tiprankstipranks
Advertisement

IHI - ETF AI Analysis

Compare

Top Page

IHI

iShares U.S. Medical Devices ETF (IHI)

Rating:74Outperform
Price Target:
IHI, the iShares U.S. Medical Devices ETF, earns a solid overall rating thanks to large positions in leaders like Intuitive Surgical and Medtronic, which show strong financial performance, positive earnings commentary, and supportive trends for future growth. Other key holdings such as Boston Scientific, Edwards Lifesciences, and Idexx Laboratories also add to the fund’s quality with robust sales and raised guidance, though many of these companies trade at premium valuations that could limit upside. The main risk is that the ETF is concentrated in the medical devices sector, so it is heavily exposed to industry-specific challenges like tariffs, regulatory changes, and high valuations across several holdings.
Positive Factors
Focused Exposure to Medical Devices
The fund gives targeted access to U.S. medical device companies, allowing investors to benefit if this specialized area of health care recovers.
Large, Established Companies in Top Holdings
Many of the biggest positions are well-known, mature health care businesses, which can offer more stability than smaller, unproven firms.
Meaningful Asset Base
The ETF manages several billion dollars in assets, suggesting it is widely used by investors and likely to remain available and tradable.
Negative Factors
Recent Weak Performance
The fund has shown weak returns so far this year and in recent months, which may concern investors looking for near-term strength.
High Concentration in a Few Stocks
A small number of holdings make up a large share of the portfolio, so poor results from these companies can strongly affect the ETF.
Single-Sector, U.S.-Only Focus
Almost all of the fund is invested in U.S. health care stocks, offering little diversification across sectors or countries.

IHI vs. SPDR S&P 500 ETF (SPY)

IHI Summary

IHI is the iShares U.S. Medical Devices ETF, which follows the DJ US Select / Medical Equipment index. It invests in U.S. companies that make medical devices and equipment used in surgeries, diagnostics, and patient care. Well-known holdings include Abbott Laboratories and Intuitive Surgical. Someone might invest in IHI to tap into the long-term growth of healthcare technology while spreading risk across many companies instead of picking a single stock. A key risk is that it is heavily focused on one sector, so its price can rise or fall sharply with changes in the healthcare and medical device industry.
How much will it cost me?The iShares U.S. Medical Devices ETF (IHI) has an expense ratio of 0.38%, which means you’ll pay $3.80 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which typically involves more specialized management compared to broad-market passive funds.
What would affect this ETF?The iShares U.S. Medical Devices ETF (IHI) could benefit from growing demand for advanced healthcare solutions and technological innovations in medical devices, driven by an aging population and increased focus on personalized medicine. However, potential risks include regulatory changes, pricing pressures, and economic downturns that may impact healthcare spending, as well as competition among top holdings like Abbott Laboratories and Intuitive Surgical. The ETF’s focus on U.S.-based companies may also limit exposure to growth opportunities in international markets.

IHI Top 10 Holdings

IHI is a pure play on U.S. medical devices, and its story right now is about a few heavyweights losing steam at the same time. Abbott and Intuitive Surgical sit at the top of the portfolio, but both have been lagging lately, turning what should be growth engines into mild headwinds. Stryker and Medtronic are also soft, adding to the drag rather than lifting returns. Even Boston Scientific, another key name, has been under pressure. With nearly all exposure in U.S. healthcare equipment, the fund is highly concentrated in one sector and a handful of big operators.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Intuitive Surgical16.48%$536.46M$170.78B-8.37%
78
Outperform
Abbott Laboratories15.90%$517.54M$158.72B-28.36%
73
Outperform
Stryker11.17%$363.44M$125.43B-10.23%
70
Outperform
Edwards Lifesciences4.82%$156.98M$48.52B10.48%
79
Outperform
Idexx Laboratories4.71%$153.24M$44.95B32.48%
78
Outperform
Medtronic4.58%$149.16M$106.97B-1.33%
80
Outperform
Resmed4.54%$147.93M$32.03B-5.18%
76
Outperform
Becton Dickinson4.53%$147.34M$43.32B-26.59%
67
Neutral
GE Healthcare Technologies Inc4.51%$146.91M$31.41B3.54%
78
Outperform
Boston Scientific4.23%$137.79M$92.25B-41.33%
79
Outperform

IHI Technical Analysis

Technical Analysis Sentiment
Negative
Last Price
Price Trends
50DMA
54.96
Negative
100DMA
58.07
Negative
200DMA
59.60
Negative
Market Momentum
MACD
-1.03
Positive
RSI
33.51
Neutral
STOCH
12.80
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IHI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 52.99, equal to the 50-day MA of 54.96, and equal to the 200-day MA of 59.60, indicating a bearish trend. The MACD of -1.03 indicates Positive momentum. The RSI at 33.51 is Neutral, neither overbought nor oversold. The STOCH value of 12.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IHI.

IHI Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$3.21B0.38%
74
Outperform
$8.59B0.35%
57
Neutral
$8.28B0.44%
65
Neutral
$2.88B0.38%
73
Outperform
$2.86B0.08%
72
Outperform
$2.31B0.54%
71
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IHI
iShares U.S. Medical Devices ETF
50.50
-9.33
-15.59%
XBI
SPDR S&P BIOTECH ETF
IBB
iShares Biotechnology ETF
IYH
iShares U.S. Healthcare ETF
FHLC
Fidelity MSCI Health Care Index ETF
FBT
First Trust NYSE Arca Biotechnology Index Fund
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement